<DOC>
	<DOC>NCT00458861</DOC>
	<brief_summary>This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.</brief_summary>
	<brief_title>BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Key Diagnosis of rheumatoid arthritis (functional class I III) at least 6 months prior to baseline Methotrexate (10 mg/week to 25 mg/week) &gt; 3 months prior to Day 0 (stable dose &gt; 4 weeks prior to Day 0) Must have had an inadequate response to antiTNF therapy due to inadequate efficacy Key Medical History Serious local infection or systemic infection within 3 months of Day 0 History (Hx) of recurrent infections requiring oral or parental antiinfective treatment Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period Laboratory Tests Clinically significant lab tests at screening; or Positive for hepatitis C antibody or hepatitis B at screening NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Active Rheumatoid Arthritis (RA)</keyword>
</DOC>